Biotech Values

[caravon]

The facts:
• Goldberg and Poorvin resignation indicates that a major conflict is taking place on the ENTA BoD.
• Both were/are the BoD Compensation Committee members.
• It is expected that, following a completion of HVC registration trials with ABBV, ENTA will be sold (unless the expected results are a complete failure)

It is quite possible that ENTA acquisition discussions are taking place already and these discussions are not going well.